|
1
|
Torre LA, Bray F, Siegel RL, Ferlay J,
Lortet-Tieulent J and Jemal A: Global cancer statistics, 2012. CA
Cancer J Clin. 2:87–108. 2015. View Article : Google Scholar
|
|
2
|
McArdle C: ABC of colorectal cancer:
Effectiveness of follow up. BMJ. 321:1332–1335. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Golfinopoulos V, Salanti G, Pavlidis N and
Ioannidis JP: Survival and disease-progression benefits with
treatment regimens for advanced colorectal cancer: A meta-analysis.
Lancet Oncol. 8:898–911. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Heinemann V, von Weikersthal LF, Decker T,
Kiani A, Vehling-Kaiser U, Al-Batran SE, Heintges T, Lerchenmüller
C, Kahl C, Seipelt G, et al: FOLFIRI plus cetuximab versus FOLFIRI
plus bevacizumab as first-line treatment for patients with
metastatic colorectal cancer (FIRE-3): A randomised, open-label,
phase 3 trial. Lancet Oncol. 10:1065–1075. 2014. View Article : Google Scholar
|
|
5
|
Katoh M and Katoh M: Notch signaling in
gastrointestinal tract (review). Int J Oncol. 30:247–251.
2007.PubMed/NCBI
|
|
6
|
Liu J, Sato C, Cerletti M and Wagers A:
Notch signaling in the regulation of stem cell self-renewal and
differentiation. Curr Top Dev Biol. 92:367–409. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Weng AP and Aster JC: Multiple niches for
Notch in cancer: Context is everything. Curr Opin Genet Dev.
14:48–54. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Weng AP, Ferrando AA, Lee W, Morris JP IV,
Silverman LB, Sanchez-Irizarry C, Blacklow SC, Look AT and Aster
JC: Activating mutations of NOTCH1 in human T cell acute
lymphoblastic leukemia. Science. 306:269–271. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Reedijk M, Odorcic S, Chang L, Zhang H,
Miller N, McCready DR, Lockwood G and Egan SE: High-level
coexpression of JAG1 and NOTCH1 is observed in human breast cancer
and is associated with poor overall survival. Cancer Res.
65:8530–8537. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Pietras A, von Stedingk K, Lindgren D,
Påhlman S and Axelson H: JAG2 induction in hypoxic tumor cells
alters Notch signaling and enhances endothelial cell tube
formation. Mol Cancer Res. 9:626–636. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Xing F, Okuda H, Watabe M, Kobayashi A,
Pai SK, Liu W, Pandey PR, Fukuda K, Hirota S, Sugai T, et al:
Hypoxia-induced Jagged2 promotes breast cancer metastasis and
self-renewal of cancer stem-like cells. Oncogene. 30:4075–4086.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Jung SG, Kwon YD, Song JA, Back MJ, Lee
SY, Lee C, Hwang YY and An HJ: Prognostic significance of Notch 3
gene expression in ovarian serous carcinoma. Cancer Sci.
101:1977–1983. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Wong SC, Lo SF, Lee KC, Yam JW, Chan JK
and Hsiao WL Wendy: Expression of frizzled-related protein and
Wnt-signalling molecules in invasive human breast tumours. J
Pathol. 196:145–153. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
McLane MA, Zhang X, Tian J, Zelinskas C,
Srivastava A, Hensley B and Paquette-Straub C: Scratching below the
surface: Wound healing and alanine mutagenesis provide unique
insights into interactions between eristostatin, platelets and
melanoma cells. Pathophysiol Haemost Thromb. 34:164–168. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Reedijk M, Odorcic S, Zhang H, Chetty R,
Tennert C, Dickson BC, Lockwood G, Gallinger S and Egan SE:
Activation of Notch signaling in human colon adenocarcinoma. Int J
Oncol. 33:1223–1229. 2008.PubMed/NCBI
|
|
16
|
Meng RD, Shelton CC, Li YM, Chetty R,
Tennert C, Dickson BC, Lockwood G, Gallinger S and Egan SE:
gamma-Secretase inhibitors abrogate oxaliplatin-induced activation
of the Notch-1 signaling pathway in colon cancer cells resulting in
enhanced chemosensitivity. Cancer Res. 69:573–582. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Peignon G, Durand A, Cacheux W, Ayrault O,
Terris B, Laurent-Puig P, Shroyer NF, Van Seuningen I, Honjo T,
Perret C and Romagnolo B: Complex interplay between β-catenin
signalling and Notch effectors in intestinal tumorigenesis. Gut.
60:166–176. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Serafin V, Persano L, Moserle L, Esposito
G, Ghisi M, Curtarello M, Bonanno L, Masiero M, Ribatti D, Stürzl
M, et al: Notch3 signalling promotes tumour growth in colorectal
cancer. J Pathol. 224:448–460. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Nam DH, Jeon HM, Kim S, Kim MH, Lee YJ,
Lee MS, Kim H, Joo KM, Lee DS, Price JE, et al: Activation of notch
signaling in a xenograft model of brain metastasis. Clin Cancer
Res. 14:4059–4066. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Yang Y, Ahn YH, Gibbons DL, Zang Y, Lin W,
Thilaganathan N, Alvarez CA, Moreira DC, Creighton CJ, Gregory PA,
et al: The Notch ligand Jagged2 promotes lung adenocarcinoma
metastasis through a miR-200-dependent pathway in mice. J Clin
Invest. 121:1373–1385. 2011. View
Article : Google Scholar : PubMed/NCBI
|
|
21
|
Wong SC, Chan CM, Ma BB, Hui EP, Ng SS,
Lai PB, Cheung MT, Lo ES, Chan AK, Lam MY, et al: Clinical
significance of cytokeratin 20-positive circulating tumor cells
detected by a refined immunomagnetic enrichment assay in colorectal
cancer patients. Clin Cancer Res. 15:1005–1012. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Wong SC, Ng SS, Cheung MT, Luk LY, Chan
CM, Cheung AH, Lee VH, Lai PB, Ma BB, Hui EP, et al: Clinical
significance of CDX2-positive circulating tumour cells in
colorectal cancer patients. Br J Cancer. 104:1000–1006. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Wong SC, Chan CM, Ma BB, Lam MY, Choi GC,
Au TC, Chan AS and Chan AT: Advanced proteomic technologies for
cancer biomarker discovery. Expert Rev Proteomics. 6:123–134. 2009.
View Article : Google Scholar : PubMed/NCBI
|
